Phase 2 trial (Lancet 2021) tested cagrilintide 0.3 mg through 4.5 mg/week as monotherapy and reported a clear dose-response, with 10.8% mean weight loss at 4.5 mg/week at 26 weeks
Sample injections within the experiment were randomized to avoid any impact of systematic instrument drift on metabolite signals
10.3390/cancers6041890 46 KimT
The TGA reports a number of adverse events and other concerns received for unapproved peptide products, which include: severe allergic reactions, requiring doses of adrenaline and hospitalisation systemic inflammatory response syndrome (SIRS) (severe inflammation in the body), requiring hospital management generalised hypersensitivity symptoms such as fullbody intense itching, palpitations, pain and sweating wide ranging body side effects, including insomnia, blurred vision, extreme tiredness, flulike illness, joint pain and skin sensitivity musculoskeletal injuries, including plantar fasciitis and Achilles tendinitis, and poor product quality, including unsealed packaging from an online supplier
It has gained significant attention in scientific and biomedical research due to its broad potential benefits related to cellular protection, tissue repair, and regenerative processes
Scientists continue to investigate its molecular structure, copper-binding characteristics and biochemical properties using controlled laboratory techniques
